3595 John Hopkins Court San Diego, CA 92121-1331 Phone: 858-202-9000 www.sequenom.com Toni Schuh, president and CEO NASDAQ:SQNM Overview Sequenom is a discovery genetics company focused on determining the medical impact of genes and genetic variations. Using a novel population genetics approach, Sequenom is systematically identifying potential disease-related genes that affect the most significant portions of the overall population. Sequenom completed its merger with Gemini Genomics

4000 Research Forest Drive The Woodlands, TX 77381-4287 Phone: 281-863-3000 www.lexicongenetics.com Arthur Sands, president and CEO NASDAQ:LEXG Overview Lexicon Genetics Inc. calls itself “a drug discovery company of the post-genome era.” It uses gene knockout technology to define the functions of genes for the discovery of pharmaceutical products. Its LexVision database is a relational database that catalogues the functions of candidate drug targets it has knocked out using its gene

12325 Emmet Street Omaha, NE 68164 Phone: 888-233-9283 www.transgenomic.com Collin D’Silva, CEO NASDAQ:TBIO Overview Transgenomic provides tools enabling researchers to discover and understand variations in the human genome with an emphasis on accelerating and improving drug development and diagnostics. Its principal technology is the WAVE System, which can detect genetic mutations without previous knowledge of their existence or position. As a result, the WAVE System provides a

215 College Road Paramus, NJ 07652-1410 Phone: 201-261-1331 www.synapticcorp.com Kathleen P. Mullinix, president, director and CEO NASDAQ:SNAP Overview Synaptic Pharmaceutical Corp. is a drug discovery company using its G protein-coupled receptors as targets for novel therapeutics and as a basis for the creation of drugs that act through these targets. Its research programs are in the areas of the central nervous system, metabolic and urologic disorders, including depression

240 East Grand Avenue South San Francisco, CA 94080 Phone: 650-624-1100 www.rigel.com James M. Gower, president and CEO NASDAQ:RIGL Overview Rigel Pharmaceuticals Inc. is a drug discovery and development company that uses functional genomics tools to discover novel drug targets. Its combinatorial biology technology is designed to identify molecules that play a role in regulating a human cell’s response to disease by testing a large number of proteins in cells to determine which

501 Canal Boulevard Suite A100 Richmond, CA 94804 Phone: 510-970-6000 www.sangamo.com Edward Lanphier, president and CEO NASDAQ:SGMO Overview Sangamo BioSciences develops and markets novel transcription factors capable of regulating genes. The company’s Universal Gene Recognition technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo

8475 Christophe-Colomb Avenue Suite 1000 Montreal, Quebec Canada H2M 2N9 Phone: 514-850-2400 www.signalgene.com Michael Dennis, president and CEO TSE:SGI Overview Established in 1991 with a focus on Alzheimer’s disease, Algne Biotechnologies Corp. changed its name to SignalGene Inc. and changed its focus to identifying disease-associated genes and validating drug candidates for major human diseases. The company has research programs in obesity, women’s health (breast cancer and

6354 Viscount Road Mississauga, Ontario Canada L4V 1H3 Phone: 905-677-1944 www.synxpharma.com Sean McNicholas, director, president and CEO TSE:SYY Overview SYN X Pharma Inc., formerly named Skye PharmaTech Inc., is a proteomics-based research and development company that uses its Proteomics Discovery Platform (PDP) to identify protein targets for the development of new drugs and to deliver highly specialized antibody-based diagnostics for the pharmaceutical industry. The company is

Locked Bag 2073 North Ryde, 1670 NSW, Australia 2113 Phone: +61 2-9889-1830 www.proteomesystems.com Keith L. Williams, CEO and director Unlisted public Australian company Overview Established in 1999, Proteome Systems is focused on the development of proteomics technology and proteomic bioinformatic systems. It has discovery research programs in infectious disease, cancer, aging and glycobiology for the development of diagnostics, therapeutics and agbiotechnology products. Products

777 Old Saw Mill River Road Tarrytown, NY 10591 Phone: 914-345-7400 www.regeneron.com Leonard S. Schleifer, founder, president and CEO NASDAQ:REGN Overview Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s focus has expanded to include programs to develop therapeutics for the treatment of obesity, rheumatoid arthritis, cancer, allergies

4390 U.S. Route One North Princeton, NJ 08540 Phone: 609-750-2200 www.orchid.com Dale Pfost, president and CEO NASDAQ:ORCH Overview Founded in 1995, Orchid BioSciences is a leading provider of products and services for single nucleotide polymorphism scoring and genetic diversity analysis. The company has developed SNP-IT a proprietary SNP analysis technology, and markets SNPstream instruments and SNPware consumables. The company provides high-throughput SNP scoring services through

The Forum 86 Milton Park Abingdon, Oxon, OX14 4RY United Kingdom Phone: +44 1235-208000 www.ogs.com Michael Kranda, CEO NASDAQ:OGSI and LSE:OGS Overview Founded in 1988 around a core glycobiology platform, Oxford GlycoSciences says it has “successfully integrated proteomics with genomics to create an innovative, proprietary drug discovery platform that allows the systematic separation, identification and characterization of proteins on an industrial scale.” Oxford’s goal is to use

104 Alexander Drive, Building 2 P.O. Box 14528 Research Triangle Park, NC 27709 Phone: 919-425-3000 www.paragen.com John Ryals, president and CEO NASDAQ:PDGM Overview Paradigm Genetics Inc. focuses on industrializing the functional genomics process for four major sectors of the global economy: human health, nutrition, crop production and industrial products. The company’s platform includes plant and fungal research, gene sequencing, bioinformatics and biochemistry. As well as using

Orchard Road, Royston Hertfordshire, SG8 5HD United Kingdom Phone: +44 (0) 1763 211600 www.pharmagene.com Alastair Riddell, CEO LSE:PGN Overview Founded in March 1996, Pharmagene plc specializes in using human tissues to aid and speed the drug discovery process. It says its mission is to provide “customers with knowledge based on human biological information that creates better drug discovery and development." Pharmagene has several drug discovery programs in various stages of

Coveham House Downside Bridge Road Cobham Surrey, KT11 3EP United Kingdom Phone: +44 (0) 1932 865065 www.proteome.co.uk Christopher Pearce, CEO LSE:PRM Overview Proteome Sciences plc has developed proprietary proteomics technology and databases. The company’s five main research areas are in cancer, neurological disease, solid organ transplant rejection, cardiovascular disease and diabetes and obesity. It has a portfolio of patents, granted and pending, on proteins found to be

3031 Research Drive Richmond, CA 94806 Phone: 510-222-9700 www.onyx-pharm.com Hollings C. Renton, chairman and CEO NASDAQ:ONXX Overview Founded in 1992, Onyx Pharmaceuticals intends to change the way cancer is treated by developing innovative treatments on therapeutic adenoviruses to multiply in malignant cells and destroy them. The company’s ONYX-15 is in Phase III clinical development for the treatment of head and neck cancer and earlier-stage development for the treatment of

6304 Spine Road Unit A Boulder, CO 80301 Phone: 303-516-8500 www.naprobio.com Leonard P. Shaykin, chairman and CEO NASDAQ:NPRO Overview Founded in 1991, NaPro BioTherapeutics is focused on the development, production and licensing of complex natural-product pharmaceuticals as well as the development and licensing of novel genetic technologies for applications in agribiotechnology, pharmacogenomics, human therapeutics and diagnostics. One of the company’s major focuses has been the

515 Galveston Drive Redwood City, CA 94063 Phone: 650-298-5300 www.maxygen.com Russell J. Howard, CEO NASDAQ:MAXY Overview Maxygen focuses on the evolution and optimization of genes and proteins to speed the process of creating commercial product leads. The company's recombination-based directed molecular evolution allows the rapid generation of product leads by integrating technologies, including proprietary directed molecular evolution technologies, to optimize genes and proteins

2501 Davey Road Woodridge, IL 60517 Phone: 630-783-4600 www.medichem.com Michael T. Flavin, chairman, president and CEO NASDAQ:MCLS Overview Founded in 1987, MediChem is a drug discovery technology and services company offering structural proteomics, early stage discovery and medicinal chemistry and a range of integrated chemistry R&D capabilities to pharmaceutical and biotechnology companies. The company's proprietary platform technologies in the areas of proteomics, biocatalysis